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ABSTRACT
Background. Radiation-associated angiosarcoma of the
breast (RAASB) is an aggressive malignancy that is
increasing in incidence. Only a few previous population-
based studies have reported the results of RAASB
treatment.
Methods. A search for RAASB patients was carried out in
the Finnish Cancer Registry, and treatment data were col-
lected to identify prognostic factors for survival.
Results. Overall, 50 RAASB patients were identified. The
median follow-up time was 5.4 years (range 0.4–15.6), and
the 5-year overall survival rate was 69%. Forty-seven
(94%) patients were operated on with curative intent.
Among these patients, the 5-year local recurrence-free
survival, distant recurrence-free survival, and overall sur-
vival rates were 62%, 75%, and 74%, respectively. A larger
planned surgical margin was associated with improved
survival.
Conclusions. We found that the majority of RAASB
patients were eligible for radical surgical management in
this population-based analysis. With radical surgery, the
prognosis is relatively good.
Globally, breast cancer (BC) is the most commonly
diagnosed cancer among women.1 Breast-conserving sur-
gery combined with radiotherapy (RT) is the preferred
local treatment of early-stage BC.2,3
Radiation-associated angiosarcoma of the breast
(RAASB) is an uncommon severe complication of breast
RT.4 In recent years, angiosarcoma has been the most
common subtype of radiation-associated sarcoma of the
breast.5 A newly published population-based study esti-
mated the risk of RAASB to be approximately 0.1%.6 It
has been postulated that the shift from radical mastec-
tomies to breast-conserving surgery has resulted in
secondary angiosarcomas arising in the breast.7
The main treatment of RAASB is surgical excision if
diagnosed in a localized stage;8–14 however, different sur-
gical approaches have previously been presented. It has
been proposed that surgery should aim at resection of all
previously irradiated skin11 with negative margins.8 How-
ever, on the other hand, one study concluded that breast-
conserving surgery was non-inferior compared with mas-
tectomy.10 In a previous study from our center, RAASB
resection was aimed at a clinical side margin of more than
3 cm; at last follow-up, six of nine patients were disease-
free.15 The benefit of adjuvant chemotherapy remains
undetermined.14 In previous studies of RAASB, the 5-year
overall survival (OS) rate has varied considerably, from
10% to 75%, respectively, likely due to the substantial
heterogeneity in RAASB treatment and study popula-
tions.6,8,12,16,17 Most previously published research on
RAASB treatment, except a recent population-based
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study,6 has mainly been performed in single tertiary cancer
centers, which might have affected the results because of
patient selection.
We set out to study the treatment and prognosis of
RAASB in a Finnish nationwide population; RAASB
patients were identified from the Finnish Cancer Registry
(FCR). Treatment of localized RAASB was assessed and
patients were followed for local or distant recurrences.
Prognostic factors for local and distant recurrences, as well
as OS, were analyzed.
METHODS
The FCR was searched for patients with previously
diagnosed invasive BC (International Classification of
Diseases for Oncology, Third Edition [ICD-O-3]18), and a
subsequent angiosarcoma, during the period 1989–2014
(ICD-O-318 morphology 9120, behavior 3), in, or close to,
the breast or chest wall. The FCR was founded in 1952 and
encompasses the entire population of Finland (currently
approximately 5.6 million inhabitants). A regulation was
administered by the National Board of Health in 1961
making the reporting of cancers to the FCR obligatory. BC
and RAASB treatment data were gathered from treating
hospitals. RAASB histopathology for the majority of cases
was confirmed in a previous study.5
Radiation-Associated Angiosarcoma of the Breast
(RAASB) Treatment and Follow-Up Assessment
Patient records and pathology reports were assessed to
document the planned surgical side margins according to
the surgery report (cm), pathological surgical margins
(cm), removed tissues (skin, subcutaneous tissue, mam-
mary gland, pectoral fascia, pectoral muscle), and possible
surgical reconstruction. The pathological surgical margin
was defined as the measurement stated in the original
pathology report. Size (defined as the longest diameter of
macroscopic tumor or skin lesion) and grade (according to
the French system19) were documented. Preoperative and
postoperative adjuvant chemotherapy and RT were regis-
tered. Patients were followed up for local recurrences and
distant metastases, and possible deaths and causes of death
were registered.
Statistical Analyses
Primary endpoints of the study were local recurrence-
free survival (LRFS), distant recurrence-free survival
(DRFS) and OS. LRFS was defined as the time from
RAASB diagnosis to the first local recurrence; DRFS was
defined as the time to first distant recurrence; and OS was
defined as the time to death from any cause, with censoring
at last follow-up. LRFS, DRFS, and OS were calculated
using the Kaplan–Meier method, while prognostic factors
for survival were analyzed using the Cox univariate model.
IBM SPSS Statistics for Windows version 25 (IBM Cor-
poration, Armonk, NY, USA) was used for all analyses.
Ethics Approval and Consent to Participate
This study was approved by the Joint Ethics Committee
of Helsinki University Hospital and the Ministry of Health
and Social Affairs. All procedures performed in studies
involving human participants were in accordance with the
ethical standards of the institutional research committee
and with the 1964 Helsinki declaration and its later
amendments or comparable ethical standards. Due to the
retrospective nature of this study, the requirement for
obtaining informed consent was waived with the permis-
sion of the Joint Ethics Committee of Helsinki University
Hospital and the Ministry of Health and Social Affairs.
RESULTS
Our search of the FCR yielded a total of 50 patients with
RAASB; all patients were Caucasian. BC characteristics
and treatment data are shown in Table 1. All patients had
received RT for BC, and the majority had received a
postoperative RT dose of 50 Gy in 2 Gy fractions (n = 38).
RAASB Characteristics
RAASB properties and treatment data are summarized
in Tables 2 and 3. All patients had a localized disease at
presentation, without distant metastases. Forty-seven
(94%) patients were operated on with curative intent, of
whom 10 (21%) were re-operated because of insufficient
surgical margins (five insufficient margins not specified in
the pathology report, three insufficient side and deep
margins, one insufficient side margin, and one insufficient
deep margin). The median pathological surgical margin
was 2.0 cm (range 0–6.0). All patients had the skin of the
breast and subcutaneous tissue excised. The surgical
operation included the resection of the pectoral fascia and
pectoral muscle in 70% and 32% of patients, respectively.
Twenty-four (51%) patients had a surgical reconstruction.
The tissue defect was most commonly reconstructed with a
pedicled latissimus dorsi flap with (seven patients) or
without (eight patients) skin grafts. Three patients with
RAASB were not operated on, two because of the extent of
disease and impaired health, and one because of a meta-
static BC. These three patients all died after a median of
44 days (range 23–58).
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Five patients received postoperative chemotherapy, of
whom three received paclitaxel, one received doxorubicin,
and one received a taxane- and anthracycline-based regi-
men after an erroneous diagnosis of BC recurrence. This
patient also received postoperative RT. The most common
indication for postoperative chemotherapy was a large
tumor size.
The treatment and outcome of patients operated with
curative intent (n = 47) are summarized in Fig. 1. The
median follow-up time was 5.4 years (range 0.4–15.6). No
patients were lost to follow-up, and 19 (40%) patients were
alive without any RAASB recurrence at last follow-up. A
local recurrence of RAASB was diagnosed in 21 of 47
(45%) patients after a median of 1.0 years (range
0.1–10.0); 19 (90%) of these patients were operated on
with curative intent, 6 of whom remained free of local and
distant recurrence at last follow-up. One additional patient
has been free of local and distant recurrence following
surgery for a second local recurrence. The median margin,
at surgery, of local recurrences was 1.0 cm (range
0.05–3.0). At the last follow-up, 7 (33%) of the 21 patients
with a local recurrence were alive without evidence of
disease, 1 (5%) was alive with a metastatic RAASB treated
with paclitaxel, 1 (5%) was alive with a metastatic
RAASB, 11 (52%) had died of RAASB, and 1 (5%) had
died of BC.
A distant metastasis of RAASB was diagnosed in 14
(30%) patients after a median of 1.1 years (range
0.4–10.5), 8 (57%) of whom had and 6 (43%) did not have
a preceding or simultaneous local recurrence. At last fol-
low-up, 11 of these 14 (79%) patients had died of
metastatic RAASB and 3 patients were alive with a
metastatic RAASB, 2 with no evidence of disease (4.4 and
5.1 years after the diagnosis of a metastatic RAASB to the
lymph nodes and treatment with paclitaxel) and 1 with
ongoing treatments for metastatic disease. The most com-
mon metastatic sites were the lungs (n = 8), liver (n = 4),
and lymph nodes (n = 4). Four patients had multiple
metastatic sites.
For operated patients (n = 47), the 5-year LRFS, DRFS,
and OS rates were 62%, 75%, and 74%, respectively
(Fig. 2). For all patients (n = 50), the 5- and 10-year OS
rates were 69% and 52%, respectively. Prognostic factors
for survival in operated patients, determined using a Cox
univariate analysis, are presented in Table 4. Only the
planned surgical side margin (hazard ratio [HR] 0.419 per
cm, 95% confidence interval [CI] 0.236–0.744; p = 0.003)
was associated with the risk of death. There was a weak
positive correlation between the planned surgical margin
and the margin assessed by the pathologist (Rs = 0.391;
p = 0.059). None of the studied factors were significantly
associated with local or distant recurrences, however there
was a non-significant trend towards improved local control
in patients operated with reconstructive surgery (HR 0.454,
95% CI 0.182–1.133; p = 0.091).
TABLE 1 Breast cancer characteristics
n = 50 %
Surgery type
Resection 39 78
Mastectomy 11 22
AJCC stage (8th edition)
IA 30 60
IIA 9 18
IIB 8 16
IIIA 2 4
IIIB 1 2
Histology
Ductal 35 70
Lobular 10 20
Mucinous 2 4
Tubular 2 4
Not assessed 1 2
Grade
1 16 32
2 26 52
3 2 4
Not assessed 6 12
Estrogen receptor
Positive 38 76
Negative 3 6
Not assessed 9 18
Progesterone receptor
Positive 31 62
Negative 10 20
Not assessed 9 18
HER2 status
Positive 1 2
Negative 20 40
Not assessed 29 58
Adjuvant endocrine therapy
No 32 64
Yes 18 36
Adjuvant chemotherapy
No 48 96
Yes 2 4
AJCC American Joint Committee on Cancer, HER2 human epidermal
growth factor receptor 2
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TABLE 2 RAASB
characteristics
n = 50 %
Age at RAASB diagnosis, years [mean (SD)] 70.4 (SD 9.1)
RAASB latency, yearsa [median (range)] 7.7 (0.6–24.5)
Size based on histopathologic report, cm [median (range)] 4.0 (0.5–16.0)
Not assessed 16 32
Location
Breast 40 80
Mastectomy scar 5 10
Upper trunk 5 10
Grade (according to the French system19)
2 6 12
3 38 76
Not assessed 6 6
RAASB radiation-associated angiosarcoma of the breast, SD standard deviation
aRAASB latency was defined as the time from radiotherapy for breast cancer to RAASB diagnosis
TABLE 3 Radiation-
associated angiosarcoma of the
breast treatment characteristics
n = 47 %
Planned surgical side margin, cm [median (range)] 4.0 (range 0.5–5.0)
Not specified 16
Pathological surgical margin, cm [median (range)] 2.0 (range 0.0–6.0)
Not assessed 12
Surgically removed tissues
Skin of breast 47 100
Subcutaneous tissue 47 100
Mammary gland 37 79
Pectoral fascia 33 70
Pectoral muscle 15 32
Reconstruction
No reconstruction 23 49
Latissimus dorsi flap 8 17
Latissimus dorsi flap with skin graft 7 15
Pedicled transverse rectus abdominis myocutaneous flap 2 4
Pedicled transverse rectus abdominis myocutaneous flap with skin graft 1 2
Pedicled thoracolateral flap 1 2
Only skin graft 5 11
Postoperative radiotherapy
No 46 98
Yes 1 2
Postoperative chemotherapy
No 42 89
Paclitaxel 3 6
Doxorubicin 1 2
Docetaxel and fluorouracil/epirubicin/cyclofosfamidea 1 2
aErroneously diagnosed as breast cancer recurrence
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DISCUSSION
Breast-conserving surgery and RT constitute the pre-
ferred local treatment of early BC. RAASB is a serious but
fortunately uncommon complication of RT. The current
study assessed RAASB treatment and prognosis in a
nationwide population. We found that a radical surgical
operation with curative intent is possible in the majority of
RAASB patients. The 5- and 10-year OS rates of 69% and
52%, respectively, compare favorably with previous stud-
ies, mostly institutional series, reporting 5-year OS rates of
10–75%,8,10,12,20 and a recent large (n = 209) nationwide
study reporting 5- and 10-year OS rates of 41% and 25%,
respectively.6 The large variation in survival is presumably
derived from the diverse patient populations.
The primary treatment of localized RAASB is surgery.
Awareness and early diagnosis of RAASB is crucial to
enable surgical treatment with curative intent. In the pre-
sent study, almost all patients (94%) underwent surgery for
RAASB. The type of surgery, amount of removed tissues,
and methods of surgical reconstruction varied consider-
ably, reflecting the nationwide patient population and
variable policies of treating hospitals. Previous research
has emphasized the importance of extensive radical oper-
ations to improve survival.11,13 In a study of 38 RAASB
patients, 36 (95%) patients were operated on with curative
intent,13 of whom 23 had a radical excision with surgical
reconstruction and 13 had a non-radical excision. The
authors observed a greater number of local recurrences in
patients with\ 1 cm margins, and concluded that at their
institution, RAASB management currently involves a
radical excision of the irradiated breast area. In a retro-
spective analysis from a tertiary center, a simple
mastectomy alone was performed in 4 of 13 surgically
treated patients.8 In the current study, the practice of
removing the irradiated breast area was not followed.
Instead, the surgical treatment consisted of a radical exci-
sion of the lesion with a median planned surgical side
Patients operated on
RAASB
(n = 47)
Alive, NED
(n = 19)
Alive, NED
(n = 6)
New local recurrence
(n = 5)
Alive, NED
(n = 1)
Operated
(n = 2)
Died of RAASB
(n = 3)
Distant recurrence
(n = 1)
Alive, metastatic
RAASB
(n = 1)
Distant recurrence
(n = 7)
Died of RAASB
(n = 6)
Operated
(n = 19)
Died of BC
(n = 1)
Alive, NED
(n = 1)
Died of RAASB
(n = 5)
Alive, metastatic BC
(n = 1)
Local recurrence
(n = 21)
Not operated, died of
RAASB
(n = 2)
Distant recurrence
(n = 6)
Alive, NED
(n = 1)
FIG. 1 Treatment and outcome of curatively treated RAASB patients. BC breast cancer, NED no evidence of disease, RAASB radiation-
associated angiosarcoma of the breast
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FIG. 2 Kaplan–Meier curves of local recurrence-free survival, distant recurrence-free survival, and overall survival in patients operated on with
curative intent (n = 47)
TABLE 4 Cox univariate analysis of hazard ratios for local recurrence-free survival, distant recurrence-free survival, and overall survival in
radiation-associated angiosarcoma of the breast patients operated on with curative intent (n = 47)
LRFS DRFS OS
p HR 95% CI p HR 95% CI p HR 95% CI
Breast cancer surgery type (mastectomy
vs. resection)
0.265 0.561 0.203–1.551 0.829 1.181 0.261–5.337 0.411 0.621 0.200–1.931
Age at RAASB diagnosisa 0.126 1.046 0.987–1.109 0.187 1.048 0.978–1.123 0.389 1.027 0.967–1.091
Year of RAASB diagnosisa 0.337 0.958 0.877–1.046 0.169 1.097 0.961–1.253 0.873 0.992 0.899–1.094
RAASB latency (years)a 0.691 1.022 0.918–1.139 0.087 1.120 0.984–1.275 0.160 1.093 0.965–1.238
Tumor size according to the pathologist’s
report (cm)a
0.814 1.014 0.906–1.134 0.253 1.075 0.950–1.216 0.413 1.054 0.929–1.196
Grade (2 vs. 3) 0.546 0.676 0.190–2.410 0.379 25.914 0.018–36,636.3 0.414 25.763 0.011–62,885
Planned surgical side margin (cm)a 0.184 0.685 0.392–1.197 0.470 0.796 0.429–1.477 0.003 0.419 0.236–0.744
Surgical margin according to the
pathologist’s report (cm)a
0.558 0.906 0.650–1.262 0.177 0.714 0.438–1.165 0.090 0.677 0.431–1.063
Extent of surgery (only skin/subcutaneous
tissue vs. removal of muscle/fascia)
0.260 0.591 0.237–1.475 0.993 1.005 0.318–3.172 0.283 0.581 0.215–1.568
Reconstructive surgery (no vs. yes) 0.091 0.454 0.182–1.133 0.293 0.555 0.185–1.663 0.266 0.567 0.209–1.540
Postoperative radiotherapy (no vs. yes) 0.686 0.048 0.000–120,815 0.125 5.103 0.638–40.833 0.119 5.232 0.654–41.850
Postoperative chemotherapy (no vs. yes) 0.993 1.007 0.230–4.407 0.521 1.652 0.357–7.653 0.235 2.170 0.604–7.805
HR hazard ratio, CI confidence interval, LRFS local recurrence-free survival, DRFS distant recurrence-free survival, OS overall survival, RAASB
radiation-associated angiosarcoma of the breast
aContinuous variable
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margin of 4.0 cm. The removal of all the irradiated breast
area may require extensive and mutilating surgical opera-
tions and surgical reconstruction. One study has suggested
that radiation-associated sarcomas arise in or at the edge of
the radiation field.21 This view was further supported by a
recent study that proposed that RAASB ‘‘arise from a field
change within the irradiated tissue’’.13 In the current study,
the tissue defect was most often covered with pedicled
latissimus dorsi flaps; however, detecting an RAASB
recurrence can be more difficult if a pedicled flap is used.
On the other hand, skin grafts may allow for a more reli-
able follow-up of the affected area.
We found that a larger planned surgical side margin was
prognostic for OS, and there was also a non-significant
trend towards an improved OS for the margin measured in
the pathologist’s report. The weaker association with the
pathologist’s assessment of the margin may reflect the
difficulty in determining the extent of RAASB due to the
multifocal growth pattern of RAASB, as previously pos-
tulated.11 While surgical margins were not statistically
significantly associated with local or distant recurrences,
they showed weaker trends towards a better outcome, with
wide CIs. Some previous studies have not found any
association between the surgical margin and a local
recurrence9,14 or OS.20,22 On the other hand, a study
including both primary and secondary angiosarcomas of
the breast reported an improved OS for patients with
negative surgical margins.23 Moreover, one study defining
radical margins as removal of all or nearly all previous
irradiated breast skin reported an improved 5-year disease-
specific survival of 86%, versus 46% for radically versus
conservatively operated patients.11 It is important to note
that most individual studies, including the present study,
are small, making assessment of prognostic factors unre-
liable. Due to its retrospective nature, the current study is
missing information regarding the planned surgical side
margin and pathological surgical side margin in a number
of patients. It is important to bear in mind the possible bias
in these results. A meta-analysis of published data com-
prising 222 RAASB patients reported that tumor size
(p\ 0.0005) and combination treatment with surgery and
irradiation (p = 0.01) improved local control significantly,
while tumor size (p\ 0.0005), and age (p = 0.048), were
prognostic for OS.24 Surgical margins were not assessed in
this meta-analysis.
A notable finding in the current study was the high risk
of local RAASB recurrence (45%). Ninety percent of these
patients underwent salvage surgery, and, at last follow-up,
only 6 of 21 (29%) patients remain alive without further
recurrences. Previous investigations of RAASB have
reported local recurrence rates ranging from 30 to 92% of
patients.8,9,12–14,17 Unfortunately, only a few of these
studies provide further follow-up data after local
recurrence. In a study of 79 RAASB patients, only 25% of
patients with a local recurrence later succumbed to
RAASB.14 Therefore, the authors suggested an intensive
treatment of local recurrences to improve survival. In
another study, a local recurrence was found in 19 of 31
(61%) patients,22 of whom 11 had a surgical excision of the
recurrence, with a median survival of 34 months compared
with 6 months in patients with no surgical intervention.
Our results corroborate the previous findings and further
support a radical surgical approach with curative intent in a
local recurrence. In our institution, the follow-up plan also
includes photographs of the affected area. The initial fol-
low-up interval is short, with gradual prolongation if no
recurrences occur.
In the current study, only one patient received postop-
erative RT and five patients received postoperative
chemotherapy. In previous studies, the use of pre- or
postoperative chemotherapy has ranged from 3% to 45%
and no firm conclusions can be drawn regarding its bene-
ficial impact.11,12,14,17,20,22 Administration of RT for
RAASB is controversial due to the previously delivered RT
for BC and the presumably RT-induced etiology of
RAASB. In the literature, the application of pre- or post-
operative RT has ranged substantially from 4 to
35%.10,12,20,25 Whether RT was administered pre- or
postoperatively is often not declared. One study reported an
improved disease-free survival at 2 years after adjuvant RT
(explicit information on RT schedule was not disclosed),
however both primary breast angiosarcoma and RAASB
were included and the study population was small
(n = 35).25 In another population-based study of exclu-
sively RAASB, no survival advantage was reported for
patients managed with both surgery and RT compared with
surgery alone.6
The results of our report are subject to at least three
limitations. First, this was a retrospective study and it is
possible that reporting to the nationwide cancer registry has
been incomplete. However, this is unlikely because the
FCR has an estimated coverage of 96% in all solid tumors
and 82.9% in tumors of bone and soft tissues.26 Second,
treatment policies may have changed during the study
period. However, the year of RAASB diagnosis did not
affect prognosis. Third, although relatively large, our
patient population is underpowered to detect prognostic
factors with a small or moderate impact. The most
important strengths originate from the population-based
patient cohort, systematic confirmation of RAASB from
hospital and pathology records, and complete follow-up of
all patients. RAASB treatment in Finland is mainly con-
centrated in the five university hospitals; however, some
patients are treated in local hospitals. It is therefore pos-
sible that RAASB treatment protocols may differ and this
may influence the results observed in this research.
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CONCLUSIONS
The present nationwide analysis of RAASB indicates
that a radical resection with wide margins was achievable
in most cases. The primary surgical intervention should
aim at the best possible local control because a significant
proportion of patients experiencing a local recurrence fur-
ther develop a metastatic disease. The 5-year OS of 74% in
surgically operated patients is higher than in most previous
series. Planned excision with wide surgical margins was
associated with an improved prognosis. The expected
growth in the number of BC survivors may possibly lead to
a further increase in RAASB incidence. Awareness of
RAASB as a late side effect of RT for BC is essential to
facilitate an early diagnosis, enable a radical surgical
treatment, and eventually improve the prognosis. Consoli-
dating RAASB treatment to high-volume centers is
advisable to ensure quality of care.
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